NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Price Target & More

$17.07 +0.62 (+3.77 %)
(As of 04/24/2018 12:36 PM ET)
Previous Close$16.45
Today's Range$16.50 - $17.40
52-Week Range$15.66 - $48.87
Volume243,784 shs
Average Volume533,990 shs
Market Capitalization$566.78 million
P/E Ratio-3.11
Dividend YieldN/A
Beta3.41

About Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics logoFive Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Receive FPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FPRX
CUSIPN/A
Phone415-365-5600

Debt

Debt-to-Equity RatioN/A
Current Ratio6.10%
Quick Ratio6.10%

Price-To-Earnings

Trailing P/E Ratio-3.11
Forward P/E Ratio-3.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.51 million
Price / Sales15.17
Cash FlowN/A
Price / CashN/A
Book Value$7.80 per share
Price / Book2.19

Profitability

EPS (Most Recent Fiscal Year)($5.38)
Net Income$-150,220,000.00
Net Margins-380.23%
Return on Equity-48.79%
Return on Assets-40.31%

Miscellaneous

Employees216
Outstanding Shares35,120,000

How to Become a New Pot Stock Millionaire

Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics Inc (NASDAQ:FPRX) announced its quarterly earnings data on Tuesday, February, 27th. The biotechnology company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.25. The biotechnology company earned $13.22 million during the quarter, compared to the consensus estimate of $9.86 million. Five Prime Therapeutics had a negative return on equity of 48.79% and a negative net margin of 380.23%. View Five Prime Therapeutics' Earnings History.

What price target have analysts set for FPRX?

4 equities research analysts have issued 1 year target prices for Five Prime Therapeutics' shares. Their predictions range from $25.00 to $60.00. On average, they anticipate Five Prime Therapeutics' stock price to reach $46.75 in the next twelve months. View Analyst Ratings for Five Prime Therapeutics.

What are Wall Street analysts saying about Five Prime Therapeutics stock?

Here are some recent quotes from research analysts about Five Prime Therapeutics stock:
  • 1. According to Zacks Investment Research, "Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. " (3/2/2018)
  • 2. Jefferies Group LLC analysts commented, "Near-term focus is on initial Ph2 data for cabiralizumab in PVNS at ASCO. Roche’s emactuzumab in PVNS showed an ~80% RR at high dose, but resulting in 2 cases of lupus per FPRX." (5/5/2017)

Who are some of Five Prime Therapeutics' key competitors?

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the folowing people:
  • Lewis T. Williams M.D. Ph.D., Executive Chairman of the Board (Age 67)
  • Aron Marc Knickerbocker MBA, President, Chief Executive Officer, Chief Operating Officer, Director (Age 47)
  • Marc L. Belsky, Chief Financial Officer, Senior Vice President (Age 61)
  • Kevin Baker Ph.D., Senior Vice President, Development Sciences (Age 56)
  • Helen Louise Collins M.D., Senior Vice President and Chief Medical Officer (Age 54)
  • Francis Willard Sarena J.D., Chief Strategy Officer and Secretary (Age 46)
  • Mark D. McDade, Lead Independent Director (Age 61)
  • Garry Nicholson, Director
  • Franklin M. Berger, Independent Director (Age 67)
  • Fred E. Cohen Ph.D. M.D., Independent Director (Age 60)

Has Five Prime Therapeutics been receiving favorable news coverage?

Press coverage about FPRX stock has been trending somewhat negative recently, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Five Prime Therapeutics earned a news impact score of -0.01 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 43.99 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Five Prime Therapeutics?

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of FPRX stock can currently be purchased for approximately $17.14.

How big of a company is Five Prime Therapeutics?

Five Prime Therapeutics has a market capitalization of $566.78 million and generates $39.51 million in revenue each year. The biotechnology company earns $-150,220,000.00 in net income (profit) each year or ($5.38) on an earnings per share basis. Five Prime Therapeutics employs 216 workers across the globe.

How can I contact Five Prime Therapeutics?

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600.


MarketBeat Community Rating for Five Prime Therapeutics (FPRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  352
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Five Prime Therapeutics (NASDAQ:FPRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Five Prime Therapeutics in the last 12 months. Their average twelve-month price target is $46.75, suggesting that the stock has a possible upside of 173.87%. The high price target for FPRX is $60.00 and the low price target for FPRX is $25.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $46.75$46.75$67.75$56.00
Price Target Upside: 173.87% upside151.61% upside54.82% upside28.79% upside

Five Prime Therapeutics (NASDAQ:FPRX) Consensus Price Target History

Price Target History for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics (NASDAQ:FPRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2018BMO Capital MarketsLower Price TargetOutperform -> Outperform$75.00 -> $60.00LowView Rating Details
2/28/2018NomuraLower Price TargetBuy -> Buy$94.00 -> $25.00HighView Rating Details
11/6/2017Royal Bank of CanadaBoost Price TargetOutperform -> Outperform$41.00 -> $50.00N/AView Rating Details
9/12/2017Jefferies GroupReiterated RatingBuy$52.00HighView Rating Details
3/24/2017CowenInitiated CoverageOutperformHighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$94.00N/AView Rating Details
11/7/2016Credit Suisse GroupReiterated RatingBuy$54.00N/AView Rating Details
10/25/2016CitigroupInitiated CoverageBuy$65.00N/AView Rating Details
8/8/2016Leerink SwannReiterated RatingOutperform$45.00 -> $58.00N/AView Rating Details
5/19/2016OppenheimerReiterated RatingOutperform$48.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Five Prime Therapeutics (NASDAQ:FPRX) Earnings History and Estimates Chart

Earnings by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics (NASDAQ:FPRX) Earnings Estimates

2018 EPS Consensus Estimate: ($4.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.55)($0.55)($0.55)
Q2 20181($1.33)($1.33)($1.33)
Q3 20181($1.33)($1.33)($1.33)
Q4 20181($1.39)($1.39)($1.39)

Five Prime Therapeutics (NASDAQ FPRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018Q4 2017($1.29)($1.04)$9.86 million$13.22 millionViewN/AView Earnings Details
11/6/2017Q3 2017($1.3520)($1.5450)$16.16 million$8.33 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.15)($1.58)$8.32 million$7.80 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.96)($1.21)$6.05 million$10.13 millionViewListenView Earnings Details
2/23/2017Q4 2016($0.57)($0.73)$7.09 million$8.30 millionViewN/AView Earnings Details
11/3/2016Q3($0.51)($0.72)$7.50 million$6.70 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.49)$6.38 million$9.23 millionViewN/AView Earnings Details
5/5/2016Q1($0.71)($0.49)$5.26 million$6.50 millionViewN/AView Earnings Details
3/10/2016Q4$9.67$10.63$354.16 million$363.34 millionViewListenView Earnings Details
11/4/2015Q315($0.99)($0.93)$4.90 million$5.90 millionViewN/AView Earnings Details
8/6/2015Q215($0.44)($0.45)$6.92 million$6.30 millionViewN/AView Earnings Details
5/13/2015Q1($0.46)($0.44)$4.77 million$4.30 millionViewListenView Earnings Details
3/17/2015Q414($0.40)($0.55)$5.39 million$4.65 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.40)($0.33)$5.22 million$6.06 millionViewN/AView Earnings Details
8/5/2014Q2 14($0.27)($0.46)$5.39 million$4.98 millionViewN/AView Earnings Details
5/8/2014Q1 2014($0.37)($0.46)ViewN/AView Earnings Details
3/25/2014Q4($0.40)($0.43)$1.52 million$3.79 millionViewListenView Earnings Details
11/12/2013($0.57)($2.74)$2.50 million$3.48 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Five Prime Therapeutics (NASDAQ:FPRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Five Prime Therapeutics (NASDAQ FPRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.40%
Institutional Ownership Percentage: 74.24%
Insider Trading History for Five Prime Therapeutics (NASDAQ:FPRX)
Insider Trading History for Five Prime Therapeutics (NASDAQ:FPRX)

Five Prime Therapeutics (NASDAQ FPRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/1/2017William R RingoDirectorSell600$45.33$27,198.00600View SEC Filing  
10/2/2017William R RingoDirectorSell1,800$40.26$72,468.001,200View SEC Filing  
9/28/2017William R RingoDirectorSell2,000$38.00$76,000.002,000View SEC Filing  
3/1/2017William R RingoDirectorSell500$46.73$23,365.00500View SEC Filing  
2/1/2017William R RingoDirectorSell500$46.17$23,085.00500View SEC Filing  
1/18/2017Francis Willard SarenaInsiderSell3,636$47.39$172,310.0482,460View SEC Filing  
1/3/2017William R RingoDirectorSell500$51.07$25,535.00500View SEC Filing  
12/23/2016Lewis T WilliamsCEOSell30,000$50.50$1,515,000.00434,047View SEC Filing  
12/1/2016William R RingoDirectorSell500$57.72$28,860.00500View SEC Filing  
11/28/2016Francis Willard SarenaInsiderSell1,710$60.14$102,839.4082,976View SEC Filing  
11/25/2016Francis Willard SarenaInsiderSell34,654$60.38$2,092,408.5294,731View SEC Filing  
11/9/2016Peder JensenDirectorSell8,130$55.30$449,589.004,065View SEC Filing  
11/1/2016William R RingoDirectorSell500$48.67$24,335.00500View SEC Filing  
10/3/2016William R RingoDirectorSell500$52.00$26,000.00500View SEC Filing  
9/1/2016William R RingoDirectorSell500$44.20$22,100.00500View SEC Filing  
8/1/2016William R RingoDirectorSell500$50.77$25,385.00500View SEC Filing  
7/27/2016Peder JensenDirectorSell12,195$49.50$603,652.5012,195View SEC Filing  
4/22/2016Franklin M BergerDirectorBuy5,000$49.47$247,350.0081,980View SEC Filing  
4/22/2016Marc BelskyCFOSell34,102$50.00$1,705,100.0088,410View SEC Filing  
4/21/2016Lewis T WilliamsCEOSell48,671$48.05$2,338,641.55341,078View SEC Filing  
4/19/2016Franklin M BergerDirectorBuy6,090$47.06$286,595.4077,890View SEC Filing  
4/15/2016Lewis T WilliamsCEOSell1,405$48.00$67,440.00341,933View SEC Filing  
4/14/2016Lewis T WilliamsCEOSell2,725$48.00$130,800.00343,253View SEC Filing  
4/6/2016Lewis T WilliamsCEOSell52,801$43.09$2,275,195.09366,477View SEC Filing  
4/6/2016Marc BelskyCFOSell20,814$45.04$937,462.5681,278View SEC Filing  
3/30/2016Francis Willard SarenaEVPSell10,000$40.01$400,100.0088,284View SEC Filing  
3/30/2016Lewis T WilliamsCEOSell23,259$40.02$930,825.18349,743View SEC Filing  
3/30/2016Marc BelskyCFOSell13,876$40.01$555,178.7685,751View SEC Filing  
3/2/2016Lewis T WilliamsCEOSell23,259$36.01$837,556.59363,611View SEC Filing  
2/4/2016Lewis T. WilliamsCEOSell71,229$33.35$2,375,487.15340,352View SEC Filing  
1/27/2016Francis Willard SarenaEVPSell30,000$35.22$1,056,600.00View SEC Filing  
10/15/2015Adage Capital Partners Gp LlcMajor ShareholderSell125,000$27.75$3,468,750.00View SEC Filing  
10/15/2015Lewis T. WilliamsCEOSell72,352$27.24$1,970,868.48294,593View SEC Filing  
9/21/2015Lewis T WilliamsCEOSell2,648$22.06$58,414.88366,945View SEC Filing  
6/22/2015Lewis T WilliamsCEOSell75,000$24.67$1,850,250.00View SEC Filing  
1/28/2015Franklin M BergerDirectorBuy25,000$27.03$675,750.00View SEC Filing  
1/15/2015Franklin M BergerDirectorBuy10,049$26.17$262,982.33View SEC Filing  
11/28/2014Franklin M BergerDirectorBuy1,951$21.04$41,049.04View SEC Filing  
11/4/2014Lewis T WilliamsCEOSell32,603$13.08$426,447.24View SEC Filing  
10/30/2014Lewis T WilliamsCEOSell17,397$13.13$228,422.61View SEC Filing  
9/23/2013Brian G AtwoodDirectorBuy76,923$13.00$999,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Five Prime Therapeutics (NASDAQ FPRX) News Headlines

Source:
DateHeadline
Immune Checkpoints Activators 2018 - Competitive Landscape, Technology and Pipeline Analysis ...Immune Checkpoints Activators 2018 - Competitive Landscape, Technology and Pipeline Analysis ...
www.businesswire.com - April 21 at 8:43 AM
Five Prime Therapeutics (FPRX) Stock Rating Lowered by ValuEngineFive Prime Therapeutics (FPRX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 18 at 11:22 PM
Five Prime Therapeutics Inc (FPRX) Receives Average Recommendation of "Hold" from AnalystsFive Prime Therapeutics Inc (FPRX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 18 at 5:30 PM
Five Prime Therapeutics (FPRX) Announces Data on B7-H4 Therapeutic Antibody at 2018 AACR Annual MeetingFive Prime Therapeutics (FPRX) Announces Data on B7-H4 Therapeutic Antibody at 2018 AACR Annual Meeting
www.streetinsider.com - April 16 at 4:58 PM
Five Prime Therapeutics (FPRX) Lowered to "Strong Sell" at BidaskClubFive Prime Therapeutics (FPRX) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - April 14 at 12:49 AM
Five Prime Therapeutics (FPRX) Stock Rating Reaffirmed by Jefferies GroupFive Prime Therapeutics (FPRX) Stock Rating Reaffirmed by Jefferies Group
www.americanbankingnews.com - April 8 at 11:23 PM
Five Prime Therapeutics (FPRX) Lowered to Sell at Zacks Investment ResearchFive Prime Therapeutics (FPRX) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:52 PM
Five Prime Therapeutics (FPRX) Upgraded to "Outperform" by BMO Capital MarketsFive Prime Therapeutics (FPRX) Upgraded to "Outperform" by BMO Capital Markets
www.americanbankingnews.com - April 7 at 12:31 PM
Five Prime Therapeutics (FPRX) Stock Rating Upgraded by BidaskClubFive Prime Therapeutics (FPRX) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 4 at 12:56 PM
Five Prime Therapeutics Inc (NASDAQ:FPRX): Poised For Long-Term Success?Five Prime Therapeutics Inc (NASDAQ:FPRX): Poised For Long-Term Success?
finance.yahoo.com - April 3 at 5:05 PM
ValuEngine Upgrades Five Prime Therapeutics (FPRX) to "Sell"ValuEngine Upgrades Five Prime Therapeutics (FPRX) to "Sell"
www.americanbankingnews.com - April 3 at 3:35 PM
Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five ...Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five ...
www.prnewswire.com - April 3 at 8:57 AM
Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics Targeted Immuno-Oncology Drug Candidate BemarituzumabPersonal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics' Targeted Immuno-Oncology Drug Candidate Bemarituzumab
finance.yahoo.com - April 3 at 8:57 AM
Five Prime Therapeutics (FPRX) Price Target Raised to $50.00 at Royal Bank of CanadaFive Prime Therapeutics (FPRX) Price Target Raised to $50.00 at Royal Bank of Canada
www.americanbankingnews.com - April 1 at 8:06 PM
Five Prime Therapeutics (FPRX) Cut to "Sell" at ValuEngineFive Prime Therapeutics (FPRX) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 1 at 2:04 PM
Five Prime Therapeutics (FPRX) Downgraded by Zacks Investment Research to "Hold"Five Prime Therapeutics (FPRX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 31 at 4:56 PM
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150
finance.yahoo.com - March 28 at 4:57 PM
Five Prime Therapeutics (FPRX) Upgraded by BidaskClub to SellFive Prime Therapeutics (FPRX) Upgraded by BidaskClub to Sell
www.americanbankingnews.com - March 28 at 11:26 AM
Five Prime Therapeutics Announces Oral Presentation on FPA150 at the 2018 AACR Annual MeetingFive Prime Therapeutics Announces Oral Presentation on FPA150 at the 2018 AACR Annual Meeting
finance.yahoo.com - March 27 at 4:52 PM
Five Prime Therapeutics (FPRX) Lowered to "Sell" at BidaskClubFive Prime Therapeutics (FPRX) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM
ValuEngine Lowers Five Prime Therapeutics (FPRX) to Strong SellValuEngine Lowers Five Prime Therapeutics (FPRX) to Strong Sell
www.americanbankingnews.com - March 25 at 5:54 PM
Five Prime Therapeutics Inc (FPRX) Receives Average Recommendation of "Hold" from BrokeragesFive Prime Therapeutics Inc (FPRX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 24 at 5:40 PM
Five Prime Therapeutics (FPRX) Licenses New Drug Target to UCB - StreetInsider.comFive Prime Therapeutics (FPRX) Licenses New Drug Target to UCB - StreetInsider.com
www.streetinsider.com - March 19 at 4:52 PM
Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery PlatformFive Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform
finance.yahoo.com - March 19 at 4:52 PM
With A -128.66% Earnings Drop, Is Five Prime Therapeutics Inc’s (NASDAQ:FPRX) A Concern?With A -128.66% Earnings Drop, Is Five Prime Therapeutics Inc’s (NASDAQ:FPRX) A Concern?
finance.yahoo.com - March 16 at 8:54 AM
Comparing Myokardia (MYOK) & Five Prime Therapeutics (FPRX)Comparing Myokardia (MYOK) & Five Prime Therapeutics (FPRX)
www.americanbankingnews.com - March 15 at 1:05 AM
Five Prime Therapeutics Announces Executive Change - Business Wire (press release)Five Prime Therapeutics Announces Executive Change - Business Wire (press release)
www.businesswire.com - March 14 at 9:22 AM
Five Prime Therapeutics (FPRX) Presents At 38th Annual Cowen and Company Healthcare Conference - SlideshowFive Prime Therapeutics (FPRX) Presents At 38th Annual Cowen and Company Healthcare Conference - Slideshow
seekingalpha.com - March 13 at 6:53 PM
-$0.54 EPS Expected for Five Prime Therapeutics Inc (FPRX) This Quarter-$0.54 EPS Expected for Five Prime Therapeutics Inc (FPRX) This Quarter
www.americanbankingnews.com - March 8 at 11:20 PM
Five Prime Therapeutics to Present at Cowen and Company 38th Annual Health Care ConferenceFive Prime Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 5:18 PM
AWM Investment Company Inc. Boosts Holdings in Five Prime Therapeutics Inc (FPRX)AWM Investment Company Inc. Boosts Holdings in Five Prime Therapeutics Inc (FPRX)
www.americanbankingnews.com - March 6 at 4:45 AM
Five Prime Therapeutics Inc (FPRX) to Post FY2022 Earnings of $0.13 Per Share, Jefferies Group ForecastsFive Prime Therapeutics Inc (FPRX) to Post FY2022 Earnings of $0.13 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 5 at 9:50 AM
Five Prime Therapeutics Inc (FPRX) to Post Q1 2018 Earnings of ($0.55) Per Share, Leerink Swann ForecastsFive Prime Therapeutics Inc (FPRX) to Post Q1 2018 Earnings of ($0.55) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - March 5 at 2:22 AM
Five Prime Therapeutics (FPRX) Stock Rating Lowered by Zacks Investment ResearchFive Prime Therapeutics (FPRX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 2 at 10:52 PM
Altrinsic Global Advisors LLC Takes Position in Five Prime Therapeutics Inc (FPRX)Altrinsic Global Advisors LLC Takes Position in Five Prime Therapeutics Inc (FPRX)
www.americanbankingnews.com - March 2 at 4:10 AM
Five Prime Therapeutics (FPRX) CEO Aron Knickerbocker on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaFive Prime Therapeutics' (FPRX) CEO Aron Knickerbocker on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 1 at 8:39 AM
Five Prime Therapeutics (FPRX) Price Target Lowered to $25.00 at NomuraFive Prime Therapeutics (FPRX) Price Target Lowered to $25.00 at Nomura
www.americanbankingnews.com - February 28 at 7:58 PM
Five Prime Therapeutics, Inc. 2017 Q4 - Results - Earnings Call SlidesFive Prime Therapeutics, Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 28 at 5:36 PM
BMO Capital Markets Trims Five Prime Therapeutics (FPRX) Target Price to $60.00BMO Capital Markets Trims Five Prime Therapeutics (FPRX) Target Price to $60.00
www.americanbankingnews.com - February 28 at 11:26 AM
Five Prime Therapeutics Inc (FPRX) Receives Consensus Recommendation of "Hold" from BrokeragesFive Prime Therapeutics Inc (FPRX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 7:46 PM
Five Prime Therapeutics beats by $0.27, misses on revenueFive Prime Therapeutics beats by $0.27, misses on revenue
seekingalpha.com - February 27 at 5:31 PM
Five Prime Announces Fourth Quarter and Full Year 2017 Financial ResultsFive Prime Announces Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 27 at 5:31 PM
A Six-Pack of Biotech BetsA Six-Pack of Biotech Bets
finance.yahoo.com - February 22 at 8:47 AM
$9.86 Million in Sales Expected for Five Prime Therapeutics Inc (FPRX) This Quarter$9.86 Million in Sales Expected for Five Prime Therapeutics Inc (FPRX) This Quarter
www.americanbankingnews.com - February 22 at 8:32 AM
Five Prime Therapeutics Inc (FPRX) Expected to Post Earnings of -$1.29 Per ShareFive Prime Therapeutics Inc (FPRX) Expected to Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - February 20 at 5:14 AM
Five Prime Therapeutics (FPRX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowFive Prime Therapeutics (FPRX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 15 at 5:01 PM
Five Prime Therapeutics (FPRX) Downgraded to Sell at Zacks Investment ResearchFive Prime Therapeutics (FPRX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - February 14 at 11:42 PM
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27
finance.yahoo.com - February 14 at 9:35 AM
An Intrinsic Value Calculation For Five Prime Therapeutics Inc (NASDAQ:FPRX) Shows It’s 42.22% UndervaluedAn Intrinsic Value Calculation For Five Prime Therapeutics Inc (NASDAQ:FPRX) Shows It’s 42.22% Undervalued
finance.yahoo.com - February 14 at 9:35 AM
Five Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare ConferenceFive Prime Therapeutics to Present at LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 9:37 AM

SEC Filings

Five Prime Therapeutics (NASDAQ:FPRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Five Prime Therapeutics (NASDAQ:FPRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Five Prime Therapeutics (NASDAQ FPRX) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.